ADVERTISEMENT

OT: COVID Science - Pfizer/Moderna vaccines >90% effective; Regeneron antibody cocktail looks very promising in phase II/III trial and more

Status
Not open for further replies.
So, I was thinking (sorry) about the world needing 10 billion doses +/- over the next years. Are the syringes used for the vaccinations re-usable? Recyclable? The vision of 10 billion syringes dumped accross the planet is stark.
Hey we’ll worry about that in 2024. The reality of all this is the a toy what you posted ... the world needs anywhere between 15 to 20 billion doses nit 10 billion.That’s quite a difference.
 
Well you yourself just cited the lack of politicalization the current admin with regard to handling of the messaging. Who’s fault is that? It’s also clear there is a much more concerted effort to handle increased production and administration of vaccine in just the last week than in the prior 9 months. Great first step to speed up the process of development. Wonderful but that’s just one step. So much more could and should have been done.
So is it a distribution problem or a supply problem? You've harshly criticized both. So the Feds should have miraculously increased vaccine doses manufactured 100x, and had plans in place to get those doses in the arms of 100 million individuals. The vaccines began reaching the states 6 weeks ago.
 
  • Like
Reactions: RUBOB72
So is it a distribution problem or a supply problem? You've harshly criticized both. So the Feds should have miraculously increased vaccine doses manufactured 100x, and had plans in place to get those doses in the arms of 100 million individuals. The vaccines began reaching the states 6 weeks ago.
I have criticized the lack of effort post vaccine development. Exhaust all resources period. There did not seem to be that approach before and now there seems to be. There are also scientists and doctors answering questions, not politicians. Both things are very positive developments.
 
  • Like
Reactions: Kbee3 and Greg2020
I have criticized the lack of effort post vaccine development. Exhaust all resources period. There did not seem to be that approach before and now there seems to be. There are also scientists and doctors answering questions, not politicians. Both things are very positive developments.
Post vaccine levels ? You are talking about 6-8 weeks and most stories have been debunked about how much information was shared between the in and out going administrations. Now we are facing another big issue . Job losses and the stock market bubble all can have a severe negative impact on this going forward. Hope I’m wrong.
 
  • Like
Reactions: bac2therac
Hey we’ll worry about that in 2024. The reality of all this is the a toy what you posted ... the world needs anywhere between 15 to 20 billion doses nit 10 billion.That’s quite a difference.
10 billion or 20 billion the issue remains. That’s a lot of bio waste!
 
some of this is true, Trump was also to blame, media behavior disgusting as well
I think we can find common ground here. The media has not shone throughout this, as some outlets just wanted to hammer Trump no matter what and others wanted to give him a pass on everything - but I submit to you that if Trump had handled this like Biden is so far, he would have been re-elected easily, since he would've gotten a pass on all the deaths and illnesses (which could have been substantially less, but certainly not near zero, unless we did what China/NZ did, which wouldn't fly here) if he had truly made a good faith effort to follow the science, but he didn't.
 
As said in the summer by those paying attention Cuomo was underreporting nursing home deaths by possibly 50%
Please refer to Andrew Cuomo by his proper title “ Emmy Award Winner “ The possibility that double the 8,700 deaths to 16 k + in nursing homes. NY Attorney General Letitia James is claiming after 8-9 months and after all his phony bluster and self righteous lamenting on daily tv. Must be the NY drinking water ?
 
Please refer to Andrew Cuomo by his proper title “ Emmy Award Winner “ The possibility that double the 8,700 deaths to 16 k + in nursing homes. NY Attorney General Letitia James is claiming after 8-9 months and after all his phony bluster and self righteous lamenting on daily tv. Must be the NY drinking water ?
He cried and got the hospital ship, ventilators out the as$ the Javits Center anything he wanted. All he did with that is kill more people than any other state.
 
Must be nice to have money and get vaccinated before the people that deserve it more. People on here should listen to Bill Spadea. He is not into putting fear in people just facts. Very nice to hear someone tell the truth about this.



LOL

NJ 101.5?

If every lie they told about RU Athletics alone was posted it would crash the site.
 

The media is so biased that the NYT app sent me an alert that the NY AG from the same party as Cuomo came out and said this...

Or could just be they're reporting things that are actually happening instead of wishcasting and the NY AG is acting as an independent check which is her job...
 
  • Like
Reactions: Greg2020 and pmvon
It's so great! King Joe may have had the greatest first week as leader of our country in history. I can't wait to see how he and our new leaders in Congress lead our country to greatness. Every time he issues a wonderful, bigly executive order it's another BOOM!
It's just great to finally have a real president...with a real team and a real plan.
 
Make that 4 "B" Build Back Better Bull$hit. For months Biden trashed every move made on COVID, and he had all the answers from the cheap seats. Now he says the process was worse off than he thought, yea-OOOOOOK
"Every move" ? Lyin' Donnie's "moves" were limited to swaying to Macho Man, working on his putz, and misleading the American people.
And finally, having his fan boys try to destroy Congress and the democracy.
Lock Him Up.
 
Last edited:
As usual, great stuff with one quibble. While the anaphylaxis rate, by definition, will be greater that it was in the clinical trials, since that rate was 0.0 (no reported incidents of anaphylaxis), if one takes that number and assumes it's the "worst case" of simply 1 in about 30,000 (the number of Pfizer and Moderna people who got the vaccine, roughly) or about 30 in 1MM, the anaphylaxis rate in the general population is almost certainly going to be significantly less than that.

As per my post below, a week ago it was looking like 10 in 1MM (6 in 656K) and the latest data show it's about 5 in 1MM (11 in 2.1MM). Yes, this is above the ~1 in 1MM typical for most vaccines, but given the benefit of not getting very sick or dying (or less chance of infecting others), it's certainly worth it IMO.

But put those numbers in context: More than 2.1 million people in the United States have received a dose of a vaccine at this point. So far, according to reports, about 11 severe allergic reactions — representing about one in 190,000 doses administered — have been noted. This is still higher than the overall rate of anaphylaxis in vaccinations, at 1.3 per one million given, but that may be only because we are being much more careful about monitoring reactions at the moment.

Good news on the mRNA vaccine anaphylaxis rates: now that we've had millions vaccinated, the rate has leveled out a lower rate than was initially seen, as rates have dropped from about 10 per 1MM to 2-5 per 1MM, which is only a little bit higher than the 1-2 per 1MM we see for the influenza vaccine.

https://www.medpagetoday.com/infect..._012821&utm_term=NL_Gen_Int_Daily_News_Update

Tom Shimabukuro, MD, of the CDC, presented data showing that rates of anaphylaxis "have come down substantially" for the Pfizer/BioNTech vaccine compared with initially reported data. CDC data in early January found a rate of 11.1 per million doses administered, while the most recent data as of January 18 found the rate was 5.0 per million.

Rates of anaphylaxis for the Moderna vaccine remained "comparable," at 2.8 per million, compared with 2.5 per million from CDC data last week.
 
He cried and got the hospital ship, ventilators out the as$ the Javits Center anything he wanted. All he did with that is kill more people than any other state.
There are counterarguments to be made, but they've been made a dozen times and won't help this thread at all. It's fine to make points about aspects of the COVID response that weren't handled well (too many to count), but the "killing" talk is counterproductive, IMO.

It's so great! King Joe may have had the greatest first week as leader of our country in history. I can't wait to see how he and our new leaders in Congress lead our country to greatness. Every time he issues a wonderful, bigly executive order it's another BOOM!
I know you're just giving a bit of payback here, but if you don't mind, try to keep such comments to the CE board or other threads, as this one is teetering on being locked down or moved. Also I'd say the "King Joe" stuff looks just as childish as the King Trump stuff did the last four years and stooping isn't the way to go. IMO, of course. Thanks.

I'd make a similar appeal to several other folks in the thread on both sides. There's so many more places to argue the politics of COVID. And I was guilty of it a bit too recently, which is why I'm back to scientific posts. Thanks in advance for at least listening.
 
Some Novavax results in.

Good news.....P3 UK trial showed 89% efficacy. That includes the new UK variant.

Not so good news. Data from a P2 trial in South Africa only showed 60% efficacy. 49% if you include people in the trial that are HIV+. But that is based on very limited data, so it’s really hard to draw conclusions. Also doesn’t tell you if it protects against severe disease.

The SA variant is going to be a problem. Expect J&J data from their SA trial to not be too good.

 
Some Novavax results in.

Good news.....P3 UK trial showed 89% efficacy. That includes the new UK variant.

Not so good news. Data from a P2 trial in South Africa only showed 60% efficacy. 49% if you include people in the trial that are HIV+. But that is based on very limited data, so it’s really hard to draw conclusions. Also doesn’t tell you if it protects against severe disease.

The SA variant is going to be a problem. Expect J&J data from their SA trial to not be too good.


Considering the annual flu shot is just 67% effective (2012 data via google), is 60 really that bad?
 
Considering the annual flu shot is just 67% effective (2012 data via google), is 60 really that bad?

Not really, especially if it limits severe disease. If the worst you get is a little cold, then who cares?

I didn’t mean a problem as in we’re going to need to start all over again. Just think efficacy will take a little hit in some vaccines and we’ll probably be getting boosters in the fall.
 
If the results are good on JnJ next week how long before that one is approved and available? Also is the JnJ only one shot?
 
Some Novavax results in.

Good news.....P3 UK trial showed 89% efficacy. That includes the new UK variant.

Not so good news. Data from a P2 trial in South Africa only showed 60% efficacy. 49% if you include people in the trial that are HIV+. But that is based on very limited data, so it’s really hard to draw conclusions. Also doesn’t tell you if it protects against severe disease.

The SA variant is going to be a problem. Expect J&J data from their SA trial to not be too good.


The Times artice on Novavax's recombinant SARS-CoV-2 protein vaccine (delivered with an adjuvant to enhance uptake in the body) is excellent. Goes into great detail on the ~90% efficacy (in preventing symptomatic COVID, post 2nd shot, like the mRNA vaccines) of the phase III trials (15,000 patients) in the UK, as well as the vaccine being just about as good against the UK variant, but as you noted, the efficacy in the much smaller (4400 patients) South African trial was about 50% in all patients and 60% in non-HIV patients, indicating that the SA variant was likely able to "escape" prevention by the vaccine. However, as far as I can tell, there were no serious infections in vaccinated people.

https://www.nytimes.com/2021/01/28/health/covid-vaccine-novavax-south-africa.html

As I posted on the other day, both Moderna and Pfizer are already proactively updating their mRNA vaccines to be able to deal with the UK/SA and Brazilian variants if needed, presumably via a 3rd booster shot for those who are vaccinated and by including the new mRNA snippets in the baseline vaccine for future recipients (so 2 doses would still be enough) - although Pfizer and Moderna still expect their vaccines to be similarly effective against these variants, based on lab studies (but this isn't the same as repeating clinical trials). The article also speculates that J&J's delay in sharing results from the clinical trials may be due to less effectiveness in a South African trial. Results are now expected early next week.

The announcement from Novavax raises the stakes for Johnson & Johnson. The company was expected to announce its results as early as last weekend, and the delay has triggered speculation among scientists that the firm has also discovered that its vaccine worked less well in South African trial volunteers who were infected with the variant. In an earnings call on Tuesday, Alex Gorsky, the chief executive officer of the company, said they were looking forward to sharing results from their late-stage trial by early next week.

Since this NatGeo article, both Moderna and Pfizer/BioNTech have announced plans to develop mRNA vaccines updated to ensure a robust immune response to several of the new COVID variants now circulating. This is a precautionary step, as all indications are still that the current vaccines will be able to provide immunity to these variants (although the antibody response from the current vaccines is less active against these variants - but still considered protective - and antibodies are not the only marker of immunity). If these updated vaccines were needed, doing this work now would ensure that they could be ready in weeks. The ability to quickly update the vaccine is one of the major advantages of the mRNA platform (much faster than for the viral vector vaccines, like those by J&J and Astra-Zeneca).

https://www.newsweek.com/pfizer-fol...-vaccine-booster-shots-covid-variants-1564718
 
Last edited:
  • Like
Reactions: Greg2020
The Times artice on Novavax's recombinant SARS-CoV-2 protein vaccine (delivered with an adjuvant to enhance uptake in the body) is excellent. Goes into great detail on the ~90% efficacy (in preventing symptomatic COVID, post 2nd shot, like the mRNA vaccines) of the phase III trials (15,000 patients) in the UK, as well as the vaccine being just about as good against the UK variant, but as you noted, the efficacy in the much smaller (4400 patients) South African trial was about 50% in all patients and 60% in non-HIV patients, indicating that the SA variant was likely able to "escape" prevention by the vaccine. However, as far as I can tell, there were no serious infections in vaccinated people.

https://www.nytimes.com/2021/01/28/health/covid-vaccine-novavax-south-africa.html

As I posted on the other day, both Moderna and Pfizer are already proactively updating their mRNA vaccines to be able to deal with the UK/SA and Brazilian variants if needed, presumably via a 3rd booster shot for those who are vaccinated and by including the new mRNA snippets in the baseline vaccine for future recipients (so 2 doses would still be enough) - although Pfizer and Moderna still expect their vaccines to be similarly effective against these variants, based on lab studies (but this isn't the same as repeating clinical trials). The article also speculates that J&J's delay in sharing results from the clinical trials may be due to less effectiveness in a South African trial. Results are now expected early next week.

The announcement from Novavax raises the stakes for Johnson & Johnson. The company was expected to announce its results as early as last weekend, and the delay has triggered speculation among scientists that the firm has also discovered that its vaccine worked less well in South African trial volunteers who were infected with the variant. In an earnings call on Tuesday, Alex Gorsky, the chief executive officer of the company, said they were looking forward to sharing results from their late-stage trial by early next week.

Do you think the FDA will approve this one based on UK data or are they gonna wait until the US trial is over?
 
  • Like
Reactions: Greg2020
Status
Not open for further replies.
ADVERTISEMENT
ADVERTISEMENT